Weekly Cisplatin Treatment for Advanced Solid Tumors
Author Information
Author(s): A.S.T. Planting, M.E.L. van der Burg, M. de Boer-Dennert, G. Stoter, J. Verweij
Primary Institution: Rotterdam Cancer Institute/Daniel den Hoed Kliniek
Hypothesis
Can a short course of weekly cisplatin improve treatment outcomes in patients with advanced solid tumors?
Conclusion
Weekly administration of cisplatin in hypertonic saline is feasible and can achieve a higher dose intensity with manageable toxicity.
Supporting Evidence
- Responses were observed in head and neck cancer, melanoma, and mesothelioma.
- Ondansetron was highly effective in preventing nausea and vomiting, especially in the first weeks of treatment.
- The maximum tolerated dose was 85 mg/m2, with dose-limiting thrombocytopenia.
Takeaway
Doctors tested a new way to give cancer medicine called cisplatin to help patients with serious tumors, and it worked pretty well without making them too sick.
Methodology
Patients received six weekly cycles of cisplatin in hypertonic saline, with ondansetron as an antiemetic.
Limitations
The study had a small sample size and lacked a control group for comparison.
Participant Demographics
18 males and 7 females, median age 51 years, with various types of advanced solid tumors.
Want to read the original?
Access the complete publication on the publisher's website